{
    "2018-09-14": [
        [
            {
                "time": "",
                "original_text": "华兰生物2018半年报点评:业绩符合预期,四价流感疫苗可期",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "2018半年报",
                        "业绩",
                        "四价流感疫苗"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【兴业定量任瞳团队】基金经理揭秘系列之八：嘉实基金齐海滔",
                "features": {
                    "keywords": [
                        "兴业定量",
                        "任瞳团队",
                        "基金经理",
                        "嘉实基金",
                        "齐海滔"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "基金"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}